Does CheckMate 026 Take Bristol Out Of The End Game?

Failure of Bristol's Opdivo in patients with lower expression of PD-L-1 biomarker gives Merck's Keytruda a huge advantage in first-line lung cancer, and leaves market-leading Bristol to wait for combination data.

chess

Bristol-Myers Squibb Co. has enjoyed a long run as the golden child of immuno-oncology, but its attempt to corner an even larger section of the market appears to have lost it a shot at the biggest segment of all.

The firm's Aug. 5 announcement that its PD-1 inhibitor Opdivo missed the primary progression-free-survival endpoint in the much-anticipated CheckMate 026...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category